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Introduction
Natural killer (NK) cells are a subpopulation of lymphocytes that play an essential role in the cell-based immune defense against virus-infected and malignant cells. Various investigators have evaluated the antitumoral activity of NK cells, including the mechanisms of immunosurveillance, escape strategies of the malignant cells and risk of adverse reactions [1] [2] [3] . Cancer therapy with NK cells can be performed by two approaches: either by activation of endogenous NK cells through systemic application of cytokines [4, 5] or by adoptive transfer of ex vivoexpanded and activated autologous or donor-derived NK cells [6] [7] [8] . The latter approach includes the use of cytotoxic NK cell lines that are suitable for clinical use [9] . The human NK cell line NK-92 [10] is highly cytotoxic against malignant cells of various origin without affecting normal human cells. Based on this selectivity, the potential of NK-92 cells for adoptive therapy is currently being investigated in phase I clinical trials. In addition to parental NK-92 cells, a genetically modified variant, termed NK-92-scFv(FRP5)-zeta, expresses a chimeric antigen receptor that retargets the cytotoxic activity of NK-92 specifically to HER2-expressing cells [11] . HER2 (synonymes: HER2/neu, ErbB2) is a receptor expressed at the surface of the cell membrane. HER2 overexpression has been observed in many human tumors of epithelial origin and has been linked with cancer development and progression [12, 13] . In contrast to parental NK-92, NK-92-scFv(FRP5)-zeta cells specifically and efficiently lyse HER2-expressing tumor cells of various origins and, upon coinjection, markedly delay growth of HER2-positive tumors [11] . However, the identification of responders and non-responders to such cell-based immunotherapies still relies on the diagnosis of a decline in tumor size several weeks after cell administration. A method that would allow to label and track the administered NK cells could verify or disprove an accumulation of the cells in the tumor tissue and, thus, could identify responders and nonresponders early after cell administration.
Currently available cell labeling techniques are based on radioactive, fluorescent or (super-) paramagnetic markers [14] [15] [16] [17] [18] [19] [20] [21] . Labeling techniques with radioactive markers provide a high sensitivity but limited spatial resolution and the risk of radiotoxic cell damage [14] [15] [16] [17] . Labeling techniques with fluorescent markers provide a high sensitivity, but limited anatomical resolution, and are currently restricted to experimental applications [18, 19] . Labeling techniques with contrast agents for magnetic resonance (MR) imaging have the advantage to be less toxic than radioactive and fluorescent markers and to provide an anatomical resolution at a near microscopic level in vivo [17, 20, 21] . However, MR cell tracking techniques are restricted by a limited sensitivity, which requires highly efficient labeling techniques in order to load up the investigated cells with high amounts of contrast agent particles. Such optimized labeling methods have been developed before for various hematopoietic cell populations, including lymphocytes, monocytes and hematopoietc progenitor cells [17, [20] [21] [22] [23] [24] [25] [26] . For nonphagocytic cell types, such labeling techniques required transfection, i.e., internalization of contrast agents into the cells with the help of liposomes, proteins or viral vectors [17, [20] [21] [22] [23] [24] [25] . Genetically engineered lymphocytes already underwent a transfection process in order to shuttle new genetic information into the cells. A subsequent secondary transfection, e.g., for purposes of contrast agent internalization, has a known lower efficiency than the primary transfection. Therefore, cell labeling protocols for genetically engineered cells need to be tailored and optimized to these cells.
The purpose of this study was (1) to optimize the labeling of genetically engineered NK-92-scFv(FRP5)-zeta and parental NK cells with iron-oxide-based MR contrast agents and (2) to monitor the accumulation of intravenously injected, iron-oxide-labeled NK-92-scFv (FRP5)-zeta (directed against HER2/neu receptors) and parental NK cells (directed against HER2/neu receptors) in HER2/neu positive mammary tumors with MR imaging.
Materials and methods
Cells and culture conditions
The continuously growing IL-2-dependent NK cell line NK-92 [23] and transduced NK-92-scFv(FRP5)-zeta cells [27, 28] expressing a chimeric antigen receptor specific to the tumor-associated ErbB2 (HER2/neu) antigen were propagated in X-VIVO 10 medium (Cambrex, Verviers, Belgium) supplemented with 5% heat-inactivated human serum and 100 units/ml IL-2 (Proleukin, Chiron, Emeryville, CA).
Prior to labeling with MR contrast agents, the cell samples were washed twice in HF/2, centrifuged, and the resultant cell pellet was resuspended with 1 ml of DMEM (Dulbecco's Modified Eagles Medium, Gibco). The number of investigated cells was counted in a cell counter prior to each experiment.
Contrast media and cell labeling procedures
Ferumoxides (Endorem; Laboratoire Guerbet, Aulnay-sousBois, France and Ferridex; Berlex Laboratories, USA) are colloid-based superparamagnetic iron-oxide particles (SPIO) with an R2/R1 relaxivity ratio (L×mmol
) of 160/40 and a diameter of 120-180 nm (mean 150 nm) [29] [30] [31] . They consist of non-stoichiometric magnetite cores, which are covered with a dextran T-10 layer and are approved as RES-specific contrast agents in the US and Europe [29] [30] [31] . NK cells with ferumoxides or ferucarbotran at a dose of 100-300 μg Fe for variable time intervals of 2-24 h in a humidified 37°/5% CO 2 incubator at 37°C.
Transfection was achieved by incubating 1×10 6 NK cells with ferumoxides or ferucarbotran at a dose of 100 μg Fe and 20 μl of liposome formulation (Lipofectin, Life Technologies, Gibco BRL) for variable time intervals of 2-24 h in a humidified 37°/5% CO 2 incubator at 37°C. Two to four of these unilammelar liposomes (size of 100-200 nm) associate with a single contrast agent molecule or particle, the lipid complex fuses with the cell plasma membrane and delivers the contrast agent to the cell cytosol [33] .
Electroporation was performed using an electroporator (Amaxa Biosystems, Köln, Germany) and a dedicated nucleofector medium for NK cells. The cells were washed once in phosphate-buffered saline, and samples of 1×10 6 NK cells each were resuspended in 2.75 ml pre-warmed supplemented nucleofector solution. Ferucarbotran and ferumoxides were added at a dose of 100 μg Fe. The cell suspensions were transferred to 2.0-mm electroporation cuvettes and nucleofected with the Amaxa Nucleofector apparatus at increasing currents for 0.5-10 s. Cell concentration, contrast-agent concentration and buffer volume were kept constant throughout all experiments. After electroporation, the cells were immediately suspended in 2.0 ml of complete medium, transferred to 12-well plates and allowed to recover in a humidified 37°/5% CO 2 incubator for 24 h [34] .
In vitro studies After the labeling procedure described above, the cells were washed at least three times with HEPES. Then, the cells were centrifuged and the cell pellets were evaluated by MR imaging at 1.5 T, using the pulse sequence protocol described below. After completion of the imaging procedures, the cell probes were further analyzed with viability tests, spectrometry and Prussian blue stains.
Cell viability was determined by the Trypan blue exclusion test and the MTT test. For the Trypan blue exclusion test, 2.5×10 5 NK cells as well as non-labeled controls were exposed to trypan blue and the relative number of non-stained, viable cells to the number of stained, non-viable cells was calculated. For the MTT test, multiple samples of 100 μl cell suspension containing 5×10 4 NK cells/ml were incubated for 4 h with 10 μl of MTT solution (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide, conc. 5 mg/ml), and the development of formazan chrystals was determined by spectrometry. Formazan chrystals develop in living cells (detected by light absorbance at 550-570 nm), while dead cells do not form formazan chrystals. These tests were performed at least three times for both cell types before and after labeling by an independent observer, who was blinded to the labeling procedure.
The iron (Fe)-concentration within iron-oxide-labeled cells was quantified by atomic absorption spectrometry (AAS) using a polarized Zeeman atomic absorption spectrometer (Hitachi, model Z-8200, Japan). If necessary, the cell suspensions were diluted with 0.05 M HCl. For the Fe measurements, the spectrophotometer was set to 248.3 nm and calibrated with six standards, containing 89.55-3,582 μmol/l Fe in 0.05 M HCl. For quality control, normal and abnormal lyphochek controls (Bio-Rad Laboratories, Munich, Germany) were used.
For Prussian blue stains, samples of labeled and nonlabeled NK cells were centrifuged, transferred to glass slides, fixed with Merck fixation and stained with Prussian blue according to the method of Pearl to identify intracytoplasmatic iron-oxide contrast-agent particles.
In vivo studies
The study was performed according to the guidelines of the National Institutes of Health and the recommendations of the committee on animal research at our institution; 2.5-5×10 6 NIH 3T3 HER2/neu receptor positive tumor cells (mouse sarcoma cell line) were injected into the mammary fat pad of six 10-week-old female nude Balb/cAnNCrl mice (Charles River Laboratories, Sulzfeld, Germany) with a body weight of 21-24 g. Tumor development and growth was monitored by daily inspection and palpation. The tumors were allowed to grow for 14-20 days to a size of 1-1.5 cm. Then, MR imaging was performed before and after injection of 5×10 6 ferucarbotran-labeled cells into the tail vein of the tumor-bearing mice: three mice received injections of labeled NK-92-scFv(FRP5)-zeta cells (directed against HER2/neu receptors) and three control mice received injections of labeled parental NK-92 cells (not directed against HER2/neu receptors).
All animals were anesthetized for the cell injections with ether. Anesthesia for MR imaging procedures was induced by an intraperitoneal injection of a combination of 0.5 mg/kg Medetomidin (Dormitor), 5 mg/kg Midazolam (Dormicum) and 0.05 mg/kg Fentanyl (Fentanyl). After completion of the imaging experiments, 2.5 mg/kg Atipamezol (Antisedan), 0.5 mg/kg Flumazenil (Anexate) and 1.2 mg/kg Naloxon (Narcanti) were given as antagonists to awake the animals. According to the veterinarians of our team, this antagonized anesthesia provides the least impairment of the animals. After completion of the final MR imaging studies, 24 h after NK cell injection, the animals were killed by an intracardial injection of an overdose of narcoren (pentobarbital). The tumors as well as samples from the liver and spleen were excised postmortem, fixed in 10% buffered formalin solution, embedded in paraffin and processed for standard histopathology (H&E staining.). In addition, anti-CD 57 immunohistochemistry stains, directed against the NK-cells, were performed to determine an NK-cell accumulation in these tissues.
Magnetic resonance imaging MR imaging was performed using a clinical 1.5-T MR scanner (Philips Gyroscan Intera, Best, The Netherlands) and a dedicated birdcage coil for high resolution MR imaging (Medical Advances, Milwaukee, WI) with a diameter of 11×11×6 cm.
For in vitro studies, the test tubes with centrifuged cell pellets were placed into a water-containing plastic container and this container was positioned into the birdcage coil. For the in vivo studies, the animals were placed prone into the coil. Cells and animals were evaluated with coronal T1-weighted 3D FFE 40°/25/2.7 (α/TR/TE) and coronal T2*-weighted 3D FFE 20°/25/12 (α/TR/TE) sequences with a FOV of 100×80 mm, a 2 pixel matrix, two acquisitions and an effective slice thickness of 400 μm. The in-plane spatial resolution of the MR images is 200×150 μm. In vivo studies in mice were performed prior to as well as 12 and 24 h after intravenous NK cell injection.
For MR data analysis, average signal intensities (SI) of cell pellets, tumors, liver and background noise were measured by operator-defined regions-of-interests (ROI). The size of the ROIs depended on the cell pellet diameter with a minimum of 10 pixels per region. The measured SI data were normalized by the background noise and expressed as signal-to-noise ratios: SNR = SI tissue / SI background . The difference in SI of the target tissues before and after injection of iron oxide-labeled NK cells was calculated as ÁSI ¼ SI post À SI pre À Á =background noise [35] .
Statistical analysis
ΔSI data were displayed as means and standard errors of the means. To compare differences in ΔSI data between different time points after NK cell injection, an analysis of variance for repeated measurements was used. Mean data were compared using the Scheffe's test. Statistical significance was assigned if P<0.05. All statistical computations were processed using Statview 4.1 software (Abacus, Berkeley, CA).
Results
In vitro studies
For all investigated labeling techniques, ferucarbotran was more efficient than ferumoxides (Fig. 1, Table 1 ), and labeling of parental NK-92 cells was more efficient than labeling of NK-92-scFv(FRP5)-zeta cells. In parental NK-92 cells, the maximal iron-oxide uptake could be achieved by adding lower concentrations of iron oxides or by shorter incubation periods as compared to the NK-92-scFv (FRP5)-zeta cells. However, the maximal achievable ironoxide uptake for both cell types was not significantly different (Table 1 , P>0.05). Therefore, all subsequent labeling protocols were optimized for the NK-92-scFv (FRP5)-zeta cells and then also applied to the parental NK cells in order to provide a comparable setup (Table 1) .
Effective labeling of NK-92 cells resulted in a marked signal decline of iron-oxide labeled cells on T2*-weighted MR images (Fig. 1) . The intracellular iron-oxide uptake was quantified by spectrometry (Table 1 ) and proven by Prussian blue stains (Figs. 2, 3) . Simple incubation resulted in only minor labeling of cells with ferucarbotran and no detectable cell labeling with ferumoxides, while electroporation and lipofection provided an effective cell labeling with both, ferucarbotran and ferumoxides (Fig. 1) .
Electroporation caused cell labeling within a few milliseconds, but reduced the viability of the cells significantly (P<0.05) (Fig. 2) , thereby necessitating additional cell culture time for cell recovery. Without electroporation, 97-98% or the investigated cells were viable, while at 48 h after electroporation, less than 80% of the cells were viable (Fig. 2) . Using different currents and exposure times, a maximum of 50-60% of the cells could be labeled with iron oxides.
Lipofection caused a linearly increasing cellular uptake of both, ferumoxides and ferucarbotran, with increasing incubation times up to 24 h. Further prolonged incubation times up to 48 h did not further increase the cellular iron uptake. Cell viability, determined by Trypan blue and MTT tests, did not change significantly with increasing incubation periods (P>0.05). Increasing iron oxide concentrations also increased cellular iron oxide uptake, but were inversely related to cell viability with minor, non-significant impairment compared to controls (P>0.05; Fig. 3 ). Lipofection with 100 μg Fe for 24 h (ferucarbotran) resulted in labeling of 60% of the cells with a preserved viability of 92%. Lipofection with 200 μg Fe for 24 h (ferucarbotran) resulted in labeling of 80% of the cells with slightly decreased viability of 88%. Using lipofection with ferucarbotran at a concentration of 100 μg Fe for 24 h, the minimal number of NK-92 cells to be detected with MR imaging was 2.5×10 5 . Follow-up studies showed a persistent labeling and a preserved viability of the cells for at least 5 days (Fig. 4) . In vivo studies
After intravenous injection of 5×10 6 ferumoxtran-labeled anti HER2/neu directed NK-92-scFv(FRP5)-zeta cells into mice with implanted HER2/neu+NIH 3T3 tumors, T2*-weighted MR images showed a marked signal decline of these tumors (Figs. 5, 6 ). This indicates an accumulation of the contrast-agent-labeled cells in the tumor tissue. Qualitatively, two of the tumors showed a homogenous signal decline (Fig. 5) , and one of the tumors showed an inhomogenous, predominantly central and dorsal signal decline (Fig. 6) . Quantified tumor SNR data were significantly different after injection (p.i.) of ferumoxtran-labeled cells compared to baseline scans before cell injection (P<0.05). The changes in tumor signal intensity were ΔSI=20.99±10.12 at 12 h p.i. and ΔSI=29.56±8.56 at 24 h p.i.. The spleen also showed a significant signal decline after cell injection (P<0.05) with ΔSI data of 7.09 ±2.48 at 12 h p.i. and 7.75±3.46 at 24 h p.i., apparently corresponding to a non-selective accumulation of some of the injected cells in this organ. The liver showed a minor, but not significant signal decline after cell injection (P>0.05; Fig. 6 ), indicative of lack of significant proportions of free iron oxides in the injected cell suspension. Liver ΔSI data were 2.69±2. 13 (Fig.  8a) . In accordance with the imaging findings, two tumors showed a diffuse accumulation of the anti HER2/neu directed NK-92 cells, while one tumor showed a more focal NK cell accumulation. No apparent difference in the underlying tumor histopathology could be found to explain this variation in cell distribution in the tumor tissue. Immunohistopathologic evaluations of the controls did not show any accumulation of non-directed parental NK-92 cells in the HER2/neu + NIH 3T3 tumors (Fig. 8b) . 
Discussion
Our data showed that genetically engineered human NK-92 cells can be labeled effectively with ferucarbotran and ferumoxides using optimized lipofection and electroporation techniques. Following intravenous injection into tumor-bearing mice, the in vivo distribution and tumor accumulation of labeled cells can be tracked with MR imaging at a clinically applicable field strength of 1.5 T.
In addition, to be tailored to specific properties of already transfected NK cells, our technique provides potential advantages compared to previously described techniques for labeling of other cell types with radioactive, fluorescent or (super-) paramagnetic markers [14] [15] [16] [17] [18] [19] [20] . Our MR labeling technique is non-invasive, easy to apply, less toxic (no radiotoxic cell damage) and provides 3D imaging data with high anatomical resolution. Since we used clinically applicable contrast agents and standard MR imaging equipment, our method is in principle suited for clinical applications.
The advantage of NK cell-based immunotherapy compared to other immunotherapies, chemotherapy or irradiation is the high and selective cytotoxicity against tumor cells without toxicity against non-malignant allogeneic cells. In addition, NK cell cytotoxicity does not require sensitization and is not MHC-restricted. Based on the high intrinsic cytotoxic activity of NK-92 cells against a wide range of malignancies [1, 6, 9, 27] and the lack of toxicity and tumorigenic potential in immunodeficient SCID mice [1, 6] , phase I/II clinical trials have been initiated. Preliminary results indicate that two infusions of NK-92 cells (highest total NK-92 cell dose transfused to one patient: 9.4×10 9 cells) in children and young adults with advanced cancer are well tolerated and do not lead to toxicity [9] . PCR-based monitoring of NK-92 kinetics in the peripheral blood of the transfused patients revealed that a large portion of NK-92-cells apparently leaves the circulation within minutes after transfusion. However, as the adoptively transfused NK-92 cells were not labeled, homing of NK-92 cells to the site of the tumor could not be confirmed in these previous clinical studies. Since NKcell accumulation and infiltration in the tumor are crucial for the therapeutic efficacy, the MR imaging technique presented here could be of great importance for further developments of this anticancer immunotherapy. Using our MR imaging method, a non-invasive assessment of the presence and extent of NK cell accumulation in the tumor tissue can be obtained within 1 day after intravenous NK cell administration. This may allow more thorough longitudinal investigations of the in vivo cell biodistribution, the homing specificity of genetically engineered NK cell subtypes, potential interactions with additional chemotherapy and reasons for treatment failures. For example, differences in therapy response between diffusely and more focally NK cell accumulating tumors, as seen in this study, may be investigated. Further applications could address variations in the effectiveness of cellbased immunotherapies with different histopathologic tumor types, different tumor grades and different stages of tumor growth. In this study, genetically engineered NK-92-scFv (FRP5)-zeta cells, which were directed against HER2/ neu-receptors [11] , were investigated as a model for NKcell-based immunotherapy. As a therapeutic alternative, the humanized monoclonal HER2-specific antibody herceptin has been applied before as a monotherapy or in combination with chemotherapy protocols and provided an increased clinical benefit for a significant proportion of patients with HER2-overexpressing metastatic breast cancers [36] . However, tumor responses could not be achieved in all patients with tumors expressing high HER2/neu levels. This justifies the development of alternative, potentially more effective therapeuticals, such as the immunotherapy described here, from a clinical point of view. Cytolytic effector cells, such as the NK-92-scFv(FRP5)-zeta cells, genetically modified to carry antibody-based receptors on the surface represent tailored targeting vehicles with the potential of improved tumor localization and enhanced therapeutic efficacy [27, 28] . On the other hand, from the point of view of diagnostic imaging, the data presented here can be considered as a general proof-of-concept for in vivo monitoring of immunotherapies with MR imaging and may be applied to label and track other types of genetically engineered cells as well.
As shown by our data, labeling procedures cause a contrast agent particle uptake in only a fraction of the incubated cells and a cell-to-cell variability in labeling efficiency. We observed this non-even distribution of iron oxides within the cells with all of our experiments so far, i.e., with labeling procedures in various populations of hematopoietic cells, tumor cells and stem cells. This phenomenon of cell-to-cell variability in transfection efficiency has been recognized before and may be due to different metabolic activities, different stages in the cell cycle or different age of the cells as well as variances in random exposure of cells to the transfection agent-contrast agent particle complexes [37, 38] .
With time after the labeling, some cells die and others divide. The internalized iron-oxide particles are subsequently in part metabolized, randomly distributed between dividing cells or released by dying cells [21] . Thus, our cell tracking method provides only accurate information about homing of the labeled cells in the target tissue. MR signal intensity changes after several days may be due to intracellular iron oxides in original or subsequent generations of the cells, due to released interstitial iron or even due to iron that was released from the originally labeled cells and then secondarily phagocytosed by local macrophages.
We recognize the following potential limitations of our study:
Cell tracking with MR imaging has a well-known limited sensitivity compared to cell labeling techniques with radioactive tracers [14] [15] [16] [17] . Further studies have to show if our labeling method is sensitive enough for potential clinical applications. The distribution volume of the injected labeled cells is obviously higher in patients than in mice. However, the volume of the investigated tumors may not be that different. Thus, in theory, 5×10 9 labeled cells administered in humans should be equally visible in tumors with a size of up to 10 cm 3 as compared to 5×10
6 labeled cells applied in our mice with 1 cm 3 tumors. Alternative labeling techniques for cell tracking with scintigraphy or PET are available as well [14] [15] [16] [17] . However, though the sensitivity of these techniques is about 1,000-fold higher as compared to MR, their spatial resolution is limited, radioactive decay limits follow-up studies and radiotoxic cell damage could occur [14] [15] [16] [17] . MR imaging has the potential advantage of an improved, near microscopic anatomical resolution and non-invasiveness of the procedure. Among all labeling methods investigated in this study, electroporation caused the worst impairment of cell viability. The problem with the applied electroporator is that the electroporation is done via certain programs, which do not allow the investigator to recognize the absolute frequency, time and type of pulses. We could only measure relative changes in the duration and amount of energy between different programs of the system; we did not have the absolute data, which the company claims as their intellectual property. Further studies with other electroporator systems, which do allow a better recognition and more systematic variation and optimization of the applied pulses, may provide better results.
The observed signal intensity changes of the tumor tissue, respectively, liver and spleen due to accumulation of iron-oxide labeled cells, is not only determined by the quantity of the cells, but also by the compartimentalization of the contrast agent in individual cells and the distribution of the cells in the target tissue. Thus, the relationship between tissue signal intensity changes and the number of accumulated cells is not linear, and the number of cells that accumulated in the tumor tissue cannot be calculated based on our data. However, further studies could address this question and provide quantitative estimates of the accumulated cells based on R2* measurements of labeled cells and target tissues before and after cell injection.
The iron-oxide-labeled NK cells showed a preserved viability up to 5 days after the labeling procedure, and they were able to migrate and home in the tumor tissue as previously observed in non-labeled cells [27, 28] . In this study, we did not perform additional investigations of the cell function before and after the labeling procedure. In previous studies, we investigated the function of hematopoietic cells more extensively and did not find any impairment of the cells due to our labeling procedure [26, 39] . This is in accordance with data from the literature [17, 20, 22, 25, [40] [41] [42] . The migration properties of our cells were apparently not impaired; otherwise, they had not reached the tumor tissue after intravenous administration.
Further studies have to prove that the ability of the labeled NK cells to lyse tumor cells is also preserved.
In this study, the cells showed a persistant labeling and detectability by MR for at least 5 days. Further follow-up studies are warranted to investigate the long-term pharmacokinetics and elimination of the internalized iron oxides, which would be expected to parallel the welldocumented pharmacokinetics of the same iron-oxide compounds after intravenous administration, i.e., the dextran coat is degraded and eliminated via the kidneys, whereas the iron oxides are distributed to the normal iron metabolism, such as heme synthesis or storage in the liver [29, 31] . Of note, ferucarbotran showed an excellent safety profile in phase I-III studies [31, 32] .
In summary, human natural killer cells can be labeled with MR contrast agents that are FDA-approved or that are being evaluated for approval, and the in vivo distribution of these labeled cells can be depicted non-invasively using a clinical 1.5-T MR scanner. This MR-based NK cell tracking technique may improve our understanding of new cell-based immunotherapies and may be clinically applicable to monitor NK cell homing and engraftment in human tumors.
